Acute Decompensated Heart Failure

Among patients with acute decompensated heart failure, device-based thoracic duct decompression demonstrated the ability to reduce congestion safely, according to results of a first-in-human study.

Adults with ACS and acute decompensated HF are twice as likely to die of any cause within 1 year if admitted on weekends or holidays vs. weekdays, independent of age or hemodynamic status or traditional CV risk factors, researchers reported.

PHILADELPHIA — A novel smartphone-based speech analysis technology predicted worsening heart failure that could lead to hospitalization, according to results of a study presented at the American Heart Association Scientific Sessions.

Early data show that thoracic duct decompression with a novel catheter-based system on top of IV loop diuretics safely lowered congestion in patients with acute decompensated HF compared with diuretics alone.

IV acetazolamide or placebo for decongestion in patients with acute decompensated HF on loop diuretics.

In the ADVOR trial, the addition of IV acetazolamide to standard IV loop diuretics improved acute congestion at 3 days in nearly 50% more patients vs. placebo in the setting of acute decompensated HF and volume overload.

Allogeneic mesenchymal precursor cells to treat persistent HF with reduced ejection fraction.

Automated speech analysis using a smartphone app may be able to detect pulmonary fluid overload in adult patients hospitalized with acute decompensated HF, according to research published in JACC: Heart Failure.

Aggressive BP lowering reduced acute decompensated HF events in SPRINT, but subsequent HF readmission and mortality did not differ between patients with reduced or preserved ejection fraction, researchers reported.

In the DREAM-HF trial, mesenchymal precursor cell therapy did not meet the primary endpoint of improvement in recurrent nonfatal decompensated HF events, but did reduce risk for nonfatal MI or stroke in certain patients with HF.